| scholarly article | Q13442814 |
| P356 | DOI | 10.2807/1560-7917.ES2015.20.4.21022 |
| P698 | PubMed publication ID | 25655053 |
| P2093 | author name string | Y Li | |
| M Petric | |||
| C Chambers | |||
| S J Drews | |||
| M Krajden | |||
| K Fonseca | |||
| J A Dickinson | |||
| G De Serres | |||
| D M Skowronski | |||
| T L Kwindt | |||
| A Eshaghi | |||
| H Charest | |||
| J B Gubbay | |||
| S Sabaiduc | |||
| A L Winter | |||
| C Martineau | |||
| N Bastien | |||
| P2860 | cites work | Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. | Q50801938 |
| Live attenuated versus inactivated influenza vaccine in infants and young children. | Q55043222 | ||
| FastTree 2--approximately maximum-likelihood trees for large alignments | Q28748616 | ||
| Predicting the evolution of human influenza A. | Q30011145 | ||
| Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. | Q30360290 | ||
| Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses | Q30419865 | ||
| Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates | Q33554684 | ||
| Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? | Q33990541 | ||
| Serologic assays for influenza surveillance, diagnosis and vaccine evaluation | Q34194336 | ||
| Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons | Q34393525 | ||
| Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses | Q35130915 | ||
| Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility | Q35715694 | ||
| Variable efficacy of repeated annual influenza vaccination | Q36705674 | ||
| Influenza vaccine effectiveness in the community and the household | Q36956943 | ||
| Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines | Q37208841 | ||
| Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. | Q42237299 | ||
| Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine | Q42242172 | ||
| Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution | Q42253862 | ||
| Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma | Q44070675 | ||
| A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season | Q47843797 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | Canada | Q16 |
| P577 | publication date | 2015-01-29 | |
| P1433 | published in | Eurosurveillance | Q14565070 |
| P1476 | title | Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. | |
| Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015 | |||
| P478 | volume | 20 |
| Q35908444 | "Crude Vaccine Effectiveness" Is a Misleading Term in Test-negative Studies of Influenza Vaccine Effectiveness |
| Q36991782 | A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season |
| Q37581851 | A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants |
| Q36333306 | A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation |
| Q45778868 | A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. |
| Q57094841 | Adjuvanted influenza vaccines |
| Q64080890 | Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans |
| Q35956533 | Detailed Report on 2014/15 Influenza Virus Characteristics, and Estimates on Influenza Virus Vaccine Effectiveness from Austria's Sentinel Physician Surveillance Network |
| Q50943612 | Detection of influenza A(H3N2) clade 3C.2a viruses in patients with suspected mumps in British Columbia, Canada, during the 2014/15 influenza season. |
| Q35887298 | Early estimates of 2014/15 seasonal influenza vaccine effectiveness in preventing influenza-like illness in general practice using the screening method in France |
| Q49204982 | Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. |
| Q41932736 | Effect of Priming With Seasonal Influenza A(H3N2) Virus on the Prevalence of Cross-Reactive Hemagglutination-Inhibition Antibodies to Swine-Origin A(H3N2) Variants |
| Q30403059 | Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain |
| Q39438313 | Effectiveness of seasonal influenza vaccine in Australia, 2015: An epidemiological, antigenic and phylogenetic assessment |
| Q40357312 | Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results |
| Q40015287 | Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. |
| Q39680416 | Effectiveness of the 2013 and 2014 Southern Hemisphere Influenza Vaccines Against Laboratory-confirmed Influenza in Young Children Using a Test-negative Design, Bangkok, Thailand |
| Q55114818 | Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. |
| Q36249828 | Emergence of Hemagglutinin Mutations During the Course of Influenza Infection |
| Q40670577 | Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. |
| Q47363883 | Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016. |
| Q39629427 | Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis |
| Q36167993 | H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps |
| Q36418145 | Hemagglutinin Gene Clade 3C.2a Influenza A(H3N2) Viruses, Alachua County, Florida, USA, 2014-15. |
| Q39813822 | I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? |
| Q30392456 | Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice |
| Q30391418 | Infant Respiratory Outcomes Associated with Prenatal Exposure to Maternal 2009 A/H1N1 Influenza Vaccination |
| Q38406947 | Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza Higher Than Expected in Hospitalized Adults: 2014-2015. |
| Q36111407 | Influenza epidemiology and influenza vaccine effectiveness during the 2014-2015 season: annual report from the Global Influenza Hospital Surveillance Network |
| Q99592761 | Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective |
| Q30152027 | Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic |
| Q40925285 | Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014. |
| Q40765540 | Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/15 season. |
| Q37134994 | Influenza: Can we cope better with the unpredictable? |
| Q38415770 | Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season |
| Q37652088 | Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. |
| Q52623520 | Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. |
| Q35705382 | Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015 |
| Q64117926 | Molecular epidemiology survey and characterization of human influenza A viruses circulating among Palestinians in East Jerusalem and the West Bank in 2015 |
| Q49409333 | Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy |
| Q40935953 | Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses |
| Q37331091 | Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada |
| Q90457627 | Preventive and protective measures reducing influenza transmission in general practice: a systematic review |
| Q40139850 | Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice |
| Q26781949 | Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults |
| Q53835317 | The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies. |
| Q40913609 | Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial |
| Q37623618 | Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan |
| Q39961932 | Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. |
| Q89892835 | Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season |
| Q38803189 | Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies |
| Q30390938 | Viral vector-based influenza vaccines |
| Q40430942 | ViroSpot microneutralization assay for antigenic characterization of human influenza viruses |
| Q39884379 | Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. |
| Q47595282 | Whole genome sequencing identifies influenza A H3N2 transmission and offers superior resolution to classical typing methods |
Search more.